A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
Stopped Study terminated early 22Feb2010 with only 4 participants due to business reasons.
Conditions
- Colon Cancer
- Rectal Cancer
Interventions
- BIOLOGICAL: Cetuximab
- DRUG: Irinotecan
- BIOLOGICAL: IMC-A12 (cixutumumab)
Sponsor
Eli Lilly and Company
Collaborators